On October 1, 2014 Innate Pharma reported that a new Phase I combination trial with lirilumab, a first-in-class NK cell checkpoint inhibitor, was published on ClinicalTrials.gov: “A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma” (study identifier: NCT02252263) (Press release Innate Pharma, OCT 1, 2014, View Source [SID:1234500773]).

Lirilumab is licensed to Bristol-Myers Squibb Company (NYSE: BMY) and this Phase I trial is being conducted by Bristol-Myers Squibb.

Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, said: “Therapeutic antibodies that act by inducing antibody-mediated cellular cytotoxicity (ADCC), such as elotuzumab, are being investigated as potential therapies for cancer treatment. We are excited to learn more about how elotuzumab and lirilumab work together in patients with multiple myeloma, an area where there is a high unmet need for new treatment options.”